Emily Bodnar
Stock Analyst at H.C. Wainwright
(3.31)
# 2,282
Out of 4,402 analysts
632
Total ratings
33.5%
Success rate
2.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintained: Buy | $70 | $48.05 | +45.68% | 10 | Jun 9, 2026 | |
| ARTV Artiva Biotherapeutics | Maintained: Buy | $35 | $8.00 | +337.50% | 9 | Jun 8, 2026 | |
| RCUS Arcus Biosciences | Maintained: Buy | $32 | $23.30 | +37.34% | 18 | Jun 3, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $38 | $9.75 | +289.74% | 46 | Jun 3, 2026 | |
| AGIO Agios Pharmaceuticals | Reiterated: Buy | $50 | $28.77 | +73.79% | 19 | Jun 2, 2026 | |
| VTVT vTv Therapeutics | Maintained: Buy | $45 | $31.74 | +41.78% | 10 | May 26, 2026 | |
| AGEN Agenus | Maintained: Buy | $23 | $3.39 | +578.47% | 38 | May 22, 2026 | |
| PPBT Purple Biotech | Reiterated: Buy | $30 | $1.54 | +1,848.05% | 19 | May 18, 2026 | |
| SNTI Senti Biosciences Holdings | Maintained: Buy | $12 | $0.9845 | +1,118.89% | 5 | May 15, 2026 | |
| INKT MiNK Therapeutics | Maintained: Buy | $35 | $12.34 | +183.75% | 26 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $17.03 | +76.16% | 2 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $1.44 | +1,219.44% | 23 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 → $10 | $1.56 | +541.03% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $2.76 | +479.71% | 30 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $2.77 | +152.71% | 26 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 → $10 | $3.38 | +195.86% | 10 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $2.59 | +867.12% | 26 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $31 | $2.88 | +976.39% | 15 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.42 | +252.11% | 37 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.14 | - | 13 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 → $48 | $17.71 | +171.03% | 41 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $2.03 | +1,131.53% | 26 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 → $66 | $54.24 | +21.68% | 20 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 | $0.466 | +4,191.85% | 21 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $6.10 | +195.08% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $2.23 | +796.86% | 14 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.007 | - | 24 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55.78 | $3.85 | +1,348.92% | 34 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $4.78 | +3,247.28% | 32 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.46 | n/a | 22 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $2.10 | n/a | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.07 | n/a | 6 | May 22, 2024 |
TG Therapeutics
Jun 9, 2026
Maintained: Buy
Price Target: $70
Current: $48.05
Upside: +45.68%
Artiva Biotherapeutics
Jun 8, 2026
Maintained: Buy
Price Target: $35
Current: $8.00
Upside: +337.50%
Arcus Biosciences
Jun 3, 2026
Maintained: Buy
Price Target: $32
Current: $23.30
Upside: +37.34%
Olema Pharmaceuticals
Jun 3, 2026
Reiterated: Buy
Price Target: $38
Current: $9.75
Upside: +289.74%
Agios Pharmaceuticals
Jun 2, 2026
Reiterated: Buy
Price Target: $50
Current: $28.77
Upside: +73.79%
vTv Therapeutics
May 26, 2026
Maintained: Buy
Price Target: $45
Current: $31.74
Upside: +41.78%
Agenus
May 22, 2026
Maintained: Buy
Price Target: $23
Current: $3.39
Upside: +578.47%
Purple Biotech
May 18, 2026
Reiterated: Buy
Price Target: $30
Current: $1.54
Upside: +1,848.05%
Senti Biosciences Holdings
May 15, 2026
Maintained: Buy
Price Target: $12
Current: $0.9845
Upside: +1,118.89%
MiNK Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $35
Current: $12.34
Upside: +183.75%
May 15, 2026
Reiterated: Buy
Price Target: $30
Current: $17.03
Upside: +76.16%
May 14, 2026
Reiterated: Buy
Price Target: $19
Current: $1.44
Upside: +1,219.44%
May 13, 2026
Rated: Buy
Price Target: $9 → $10
Current: $1.56
Upside: +541.03%
May 13, 2026
Maintained: Buy
Price Target: $16
Current: $2.76
Upside: +479.71%
May 12, 2026
Reiterated: Buy
Price Target: $7
Current: $2.77
Upside: +152.71%
May 11, 2026
Rated: Buy
Price Target: $7 → $10
Current: $3.38
Upside: +195.86%
May 8, 2026
Maintained: Buy
Price Target: $25
Current: $2.59
Upside: +867.12%
May 8, 2026
Maintained: Buy
Price Target: $31
Current: $2.88
Upside: +976.39%
May 7, 2026
Maintained: Buy
Price Target: $5
Current: $1.42
Upside: +252.11%
May 6, 2026
Maintained: Hold
Price Target: n/a
Current: $1.14
Upside: -
May 1, 2026
Reiterated: Buy
Price Target: $49 → $48
Current: $17.71
Upside: +171.03%
Apr 2, 2026
Maintained: Buy
Price Target: $25
Current: $2.03
Upside: +1,131.53%
Mar 30, 2026
Maintained: Buy
Price Target: $55 → $66
Current: $54.24
Upside: +21.68%
Mar 30, 2026
Rated: Buy
Price Target: $20
Current: $0.466
Upside: +4,191.85%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $6.10
Upside: +195.08%
Nov 17, 2025
Reiterated: Buy
Price Target: $20
Current: $2.23
Upside: +796.86%
Nov 17, 2025
Maintained: Hold
Price Target: n/a
Current: $0.007
Upside: -
Oct 13, 2025
Maintained: Buy
Price Target: $55.78
Current: $3.85
Upside: +1,348.92%
Sep 26, 2025
Maintained: Buy
Price Target: $160
Current: $4.78
Upside: +3,247.28%
Apr 29, 2025
Rated: Hold
Price Target: n/a
Current: $5.46
Upside: n/a
Mar 31, 2025
Maintained: Buy
Price Target: $8
Current: $2.10
Upside: n/a
May 22, 2024
Rated: Hold
Price Target: n/a
Current: $4.07
Upside: n/a